1-5 of 5
MARCUS THURESSON
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

232-LB: Cardiovascular Complications in T1D and T2D Patients Show More Similarities than Differences

JAN W. ERIKSSON, JOHAN BODEGARD, ANNA NORHAMMAR, MARCUS THURESSON, DAVID NATHANSON, THOMAS NYSTROM
Journal: Diabetes
Diabetes 2019;68(Supplement_1):232-LB
DOI: https://doi.org/10.2337/db19-232-LB
Published: 01 June 2019
View article
Meeting Abstracts

6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL

LINDSAY E. CLEGG, ROBERT C. PENLAND, DAVID W. BOULTON, SRINIVAS BACHINA, MARCUS THURESSON, HIDDO L. HEERSPINK, STEPHANIE GUSTAVSON, C. DAVID SJöSTRöM, JAMES A. RUGGLES, ADRIAN F. HERNANDEZ, JOHN B. BUSE, ROBERT J. MENTZ, RURY R. HOLMAN
Journal: Diabetes
Diabetes 2019;68(Supplement_1):6-LB
DOI: https://doi.org/10.2337/db19-6-LB
Published: 01 June 2019
View article
Meeting Abstracts

206-LB: Cardiorenal Disease Is the Most Common First CV Manifestation in Type 2 Diabetes and Associated with Increased Mortality: A Large Multinational Observational Study

KARE I. BIRKELAND, JOHAN BODEGARD, MARCUS THURESSON, JAN W. ERIKSSON, ANNA NORHAMMAR, TOSHITAKA YAJIMA, ISSEI KOMURO, TAKASHI KADOWAKI
Journal: Diabetes
Diabetes 2019;68(Supplement_1):206-LB
DOI: https://doi.org/10.2337/db19-206-LB
Published: 01 June 2019
View article
Meeting Abstracts

Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group

LINDSAY CLEGG, HIDDO L. HEERSPINK, ROBERT C. PENLAND, WEIFENG TANG, DAVID W. BOULTON, SRINIVAS BACHINA, ROBERT D. FOX, PETER FENICI, MARCUS THURESSON, ROBERT J. MENTZ, ADRIAN F. HERNANDEZ, M. ANGELYN BETHEL, RURY R. HOLMAN
Journal: Diabetes
Diabetes 2018;67(Supplement_1):130-LB
DOI: https://doi.org/10.2337/db18-130-LB
Published: 01 July 2018
View article
Meeting Abstracts

Lower Risk of CV Events and Death Associated with Initiation of SGLT2 vs. DPP-4 Inhibitors—Analysis from the CVD-REAL 2 Study

SHUN KOHSAKA, CAROLYN S. LAM, DAE JUNG KIM, AVRAHAM KARASIK, NAVDEEP TANGRI, SU-YEN GOH, MARCUS THURESSON, HUNGTA CHEN, FILIP SURMONT, NIKLAS HAMMAR, PETER FENICI, MIKHAIL KOSIBOROD, CVD-REAL INVESTIGATORS AND STUDY GROUP
Journal: Diabetes
Diabetes 2018;67(Supplement_1):124-LB
DOI: https://doi.org/10.2337/db18-124-LB
Published: 01 July 2018
View article